Viveve Medical Inc (VIVE): what happened this one dived to .65 what...

~ Blue ~ · 2020-08-25T21:16:46.6600000Z

what happened this one dived to .65 what was wrong

Play Episode

4min

Proactive - Interviews for investors

EnWave expands footprint with commercial license in Japan and U.S. biopharmaceutical agreement

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce the company has signed a commercial license agreement with Hokkai Yamato Foods Japan, a leading producer of processed foods such as soups, furikake, and ochazuke. As part of the agreement, Hokkai Yamato has acquired a 10kW Radiant Energy Vacuum (REV™) machine to drive product development and support early-stage commercial production in Japan. This license grants Hokkai Yamato exclusive rights to use EnWave’s patented REV™ technology for the production of various food products within Japan. In return, Hokkai Yamato will pay royalties to EnWave, consistent with existing licensing agreements. EnWave will work closely with Hokkai Yamato to optimize product development and ensure long-term commercial success. In addition to expanding its presence in the Japanese food sector, EnWave has also signed a master service agreement with BioTechnique, a U.S.-based pharmaceutical contract manufacturer. This agreement lays the groundwork for BioTechnique to evaluate EnWave’s REV™ dehydration technology as a potential alternative to freeze-drying in biopharmaceutical applications. As part of the collaboration, BioTechnique will conduct paid testing of several liquid pharmaceutical products, drying them in vials using pilot-scale REV™ machinery at EnWave’s Innovation Center in Delta, British Columbia. If the results prove successful, BioTechnique may choose to acquire its own REV™ equipment to provide dehydration services directly to its network of leading pharmaceutical clients. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #CEOInterview #Peru #Spain #Blueberry #Snacks #Royalties #TradeMission

Proactive - Interviews for investors

Newmark Security CEO on growth drivers, expanding D2E model globally

Newmark Security PLC CEO Marie-Claire Dwek talked with Proactive's Stephen Gunnion about the company’s latest trading update, which highlighted stronger revenue performance in the second half of the financial year. Dwek said the growth was primarily driven by the Human Capital Management (HCM) division, especially in North America, where both hardware and service-related sales have increased. She explained, “The more clocks we sell, the more recurring revenue we sell, the more services we sell.” This growth model is being further supported by a Direct to End user approach, with active integrations already in place with Oracle and Workday, and further development underway with SAP. Dwek also spoke about their efforts to diversify, including moves into lower-cost market segments, which are typically dominated by Chinese manufacturers. This allows Newmark to capture new customer groups while maintaining service-based revenue opportunities. Outside North America, Newmark continues to see growth in Europe, citing customers like Marks & Spencer and Protime. The company is also building pipeline opportunities in collaboration with Oracle and is working on exclusivity in North America with one partner. Dwek described this as “a whole new market for us that was previously untapped.” For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #NewmarkSecurity #MarieClaireDwek #HCM #EnterpriseSoftware #RecurringRevenue #OracleIntegration #Workday #SAPIntegration #WorkforceManagement #TechGrowth #NorthAmericaExpansion #SecuritySolutions #HumanCapitalManagement #ProactiveInvestors #D2EModel

Proactive - Interviews for investors

Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Proactive - Interviews for investors

CleanSpace eyes 30% growth, EBITDA breakeven

CleanSpace Holdings Ltd CEO Gabrielle O’Carroll talked with Proactive about AIM's Small and Midcap Conference about the company’s growth trajectory and product innovation in powered air purifying respirators (PAPRs). CleanSpace was founded in 2009, based on an innovation developed during the SARS epidemic. The company's differentiator is its lightweight, head-mounted respirators that contrast with the bulkier waist-mounted models commonly available in the industrial market. “We are steadily approaching that breakeven EBITDA, profitable EBITDA position, which is our goal,” O’Carroll said. O’Carroll explained that CleanSpace's respirators are well suited for industrial sectors like mining, infrastructure, and petrochemicals. The products are marketed in key regions including the United States, Western Europe, and Australia. The company has 52 employees and recorded AU$9.2 million in revenue in the first half, up 26% year-over-year. CleanSpace is targeting annual revenue growth of 25–30% and expects to achieve positive EBITDA soon. To drive this, the company is focused on raising brand awareness, engaging directly with end users, and supporting occupational hygienists and safety managers. CleanSpace is also investing in R&D to support future product launches. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #CleanSpaceHoldings #IndustrialSafety #RespiratoryProtection #PAPR #WorkplaceSafety #OccupationalHealth #ASXStocks #HealthTech #EBITDA #MiningSafety #InfrastructureSafety #ProactiveInvestors

Followers	2552
Posts	112748
Boards Moderated	1
Alias Born	08/25/2010

Volume:	-
Day Range:
Bid:	0.2201
Ask:	0.23
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

VIVE Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free